Home

Home From The Editor Contact Us  

 

What's New
Facts
Talking to the MD
Online Consult
Clinical Trials
Resources

 

 

Welcome to Sarcoma.net

Welcome to Sarcoma.net, hosted by
     
         Dr. George Demetri
bullet

ASCO 2004 Annual Meeting: SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)
 

bullet

ASCO 2004 Symposium GI Sarcoma Update: ACTIVITY AND TOLERABILITY OF THE MULTI-TARGETED TYROSINE KINASE INHIBITOR SU011248 IN PATIENTS (PTS) WITH METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) REFRACTORY TO IMATINIB MESYLATE
 

bullet

Targeting the KIT Tyrosine Kinase with STI571 (Gleevec, Imatinib meslylate) in Solid Tumors: Getting the GIST of It


 


 

 

Copyright 1998- 2005 Sarcoma.net